XHE240719P83000
- 0.00
- 0.000.00%
Spdr S&P Health Care Equipment Newsroom
P/E Ratio Insights for Edwards Lifesciences
In the current market session, Edwards Lifesciences Inc. (NYSE:EW) share price is at $92.84, after a 1.00% decrease. Over the past month, the stock increased by 5.91%, but over the past year, it
(TFX) - Analyzing Teleflex's Short Interest
Teleflex's (NYSE:TFX) short percent of float has fallen 8.73% since its last report. The company recently reported that it has 620 thousand shares sold short, which is 2.09% of all regular shares
UnitedHealth, Edwards Lifesciences, First Citizens Bank And More: CNBC's 'Final Trades'
Jim Lebenthal of Cerity Partners hyped UnitedHealth Group Incorporated (NYSE:UNH) as a "solid" healthcare company in the latest edition of CNBC's "Halftime Report Final Trades." On July 9, Cantor
Argus Research Downgrades Silk Road Medical to Sell
Argus Research analyst Steve Silver downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Sell.
Silk Road Medical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 — Argus Research Downgrades Buy → Sell 06/18/2024 3.77% Lake Street $28 → $27.5 Downgrades
10 Analysts Have This To Say About Glaukos
During the last three months, 10 analysts shared their evaluations of Glaukos (NYSE:GKOS), revealing diverse outlooks from bullish to bearish.The table below offers a condensed view of their recent
Glaukos Cut as Citi Reviews U.S. MedTechs
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings
Glaukos Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 9.66% Citigroup $130 → $132 Downgrades Buy → Neutral 06/05/2024 8% Stifel $110 → $130
Analyst Ratings For AtriCure
AtriCure (NASDAQ:ATRC) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below summarizes their recent ratings, show
AtriCure Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 78.17% Needham $40 → $40 Reiterates Buy → Buy 05/02/2024 118.26% Canaccord Genuity $57 → $49 Ma
$1000 Invested In This Stock 20 Years Ago Would Be Worth $33,000 Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 10.86% on an annualized basis producing an average annual return of 19.18%. Currently, Edwards Lifesciences has a m
The Analyst Landscape: 13 Takes On Edwards Lifesciences
13 analysts have expressed a variety of opinions on Edwards Lifesciences (NYSE:EW) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table encapsulates th
Deutsche Bank's Fresh Money List for 3Q
Edwards Lifesciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 1.51% Evercore ISI Group $89 → $91 Maintains In-Line 05/30/2024 19.35% Goldman Sachs → $107 Ini
Piper Upgrades Teleflex to Overweight, Cites Expected EPS Growth
This Medical Devices Stock Has Several Catalysts, Says Bullish Analyst
Teleflex Inc (NYSE:TFX) benefited in the first quarter from the surge in the interventional segment and other tailwinds.UroLift sales in the physician's office could bottom out at $49 million in 2024
Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.; Revenue From $1.31B-$1.325B To $1.32B-$1.34B Vs...
Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.
Teleflex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 16.48% Piper Sandler $205 → $245 Upgrades Neutral → Overweight 05/03/2024 4.12% Truist Securiti
UFP Techs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 16.43% Lake Street $270 → $300 Maintains Buy 03/20/2024 -1.04% CJS Securities → $255 Initiates